Scalar Gauge Management LLC Grows Stock Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Scalar Gauge Management LLC lifted its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 21.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 383,917 shares of the company’s stock after buying an additional 66,707 shares during the period. Cellebrite DI makes up about 3.9% of Scalar Gauge Management LLC’s investment portfolio, making the stock its 11th largest position. Scalar Gauge Management LLC’s holdings in Cellebrite DI were worth $8,458,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Alliancebernstein L.P. raised its position in Cellebrite DI by 109.7% in the fourth quarter. Alliancebernstein L.P. now owns 28,633 shares of the company’s stock worth $631,000 after acquiring an additional 14,981 shares during the period. Pertento Partners LLP increased its stake in shares of Cellebrite DI by 26.7% in the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company’s stock worth $65,547,000 after purchasing an additional 626,373 shares in the last quarter. Pictet Asset Management Holding SA bought a new position in Cellebrite DI in the 4th quarter worth $283,000. Blair William & Co. IL lifted its position in Cellebrite DI by 15.7% during the fourth quarter. Blair William & Co. IL now owns 143,476 shares of the company’s stock valued at $3,161,000 after purchasing an additional 19,433 shares in the last quarter. Finally, LPL Financial LLC grew its holdings in Cellebrite DI by 39.0% during the fourth quarter. LPL Financial LLC now owns 54,402 shares of the company’s stock valued at $1,198,000 after purchasing an additional 15,267 shares during the period. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price Performance

Shares of CLBT opened at $19.46 on Monday. The firm has a market cap of $4.66 billion, a P/E ratio of -14.00, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52. Cellebrite DI Ltd. has a 1 year low of $10.25 and a 1 year high of $26.30. The company has a 50 day simple moving average of $20.85 and a two-hundred day simple moving average of $19.91.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. JPMorgan Chase & Co. raised their price objective on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Lake Street Capital lifted their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 14th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of Cellebrite DI in a research report on Thursday. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $23.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.